SOURCE: Addex Pharmaceuticals

February 16, 2010 12:26 ET

Addex to Host FY2009 Financial Results Conference Call on Feb. 23

PLAN-LES-OUATES GENEVA, SWITZERLAND--(Marketwire - February 16, 2010) - Addex Pharmaceuticals /Addex to Host FY2009 Financial Results Conference Call on Feb. 23 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Addex Pharmaceuticals (SWX: ADXN), the allosteric modulation company, will discuss its 2009 full year financial results during a conference call and webcast for investors, analysts and the media on Tuesday, 23 February 2010 at 16:00 CET. The financial results press release will be issued prior to the start of trading on the SIX Swiss Exchange stock market earlier the same day.

Addex Full Year 2009 Financial Results Conference Call:
Date: 23 February 2009
Time: 16:00 CET/15:00 GMT/10:00 EST
Dial-in numbers:

+41 91 610 56 00 (Europe)
+44 207 107 06 11 (UK)
+1 866 291 41 66 (USA)

Webcast & slides (replay and transcript) will be made available at www.addexpharma.com.

Addex Pharmaceuticals (www.addexpharma.com) utilizes its unique proprietary platform technologies to discover and develop allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. With 15 programs in development, the Addex pipeline demonstrates the productivity and broad potential of our unparalleled platform technologies. The most advanced product, ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase I testing and is scheduled to start Phase II testing for Parkinson's disease levodopa associated dyskinesia (PD-LID) later in 2010.

Our products and technology already have proven their value through our relationships with four of the top 10 pharmaceutical companies in the world. Specifically, under an agreement withOrtho-McNeil-Janssen Inc., a Johnson & Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is undergoing Phase I clinical testing and has potential for treatment of schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc., we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's disease and schizophrenia, respectively. In addition, SR-One, the corporate venture arm of GlaxoSmithKline, and Roche Venture Fund have made equity investments in Addex.

Disclaimer: The foregoing release contains forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding  allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


[HUG#1384959]

Contact Information

  • Chris Maggos
    Investor Relations & Communications
    Addex Pharmaceuticals
    +41 22 884 15 11
    Email Contact